OVERVIEW

Medical Crossfire®: Uncovering the Potential Impact of Emerging Data and Ongoing Clinical Trials in AML is organized by Physicians' Education Resource, LLC (PER).

Release Date: August 30, 2019
Expiration Date: August 30, 2020

Target Audience:
These activities are intended for medical oncologists, hematologists, and other oncology healthcare professionals interested in the latest advances in the treatment of patients with acute myeloid leukemia.

Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with acute myeloid leukemia are also invited to attend.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
To optimize outcomes for patients with acute myeloid leukemia (AML), healthcare practitioners need both access to emerging clinical data and expert guidance on how to utilize these data to optimize patient care. Numerous practice-changing developments were recently made in AML. The increase in understanding of the genetics of AML and disease-related factors has led to the development of risk stratification models to help predict the clinical course for a given patient and aid in planning a therapeutic approach. New therapy approvals in AML have rapidly altered treatment paradigms, and other agents are being evaluated in clinical trials. This advancement in treatment innovation has resulted in important competence gaps among practitioners who must decipher the best course of patient management to achieve optimal clinical outcomes. Prevention of disease relapse and improvement of clinical outcomes for patients who experience relapsed/refractory AML is a primary concern. Practitioners have a critical need to be familiar with how to apply recent data for available agents, including how to monitor for and manage treatment-related toxicities.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Identify testing strategies to stratify risk among patients with AML, methods to apply results from these tests, and ongoing monitoring strategies for patients with these tumors
• Describe results from recent clinical trials that have evaluated current and emerging treatment strategies among patients with AML
• Apply novel treatment approaches in the context of evolving treatment paradigms in the management of • AML including methods to personalize care for elderly patients or those with poor performance status
• Delineate approaches to proactively manage treatment-related toxicities that occur along the disease continuum in the care of patients with AML.